Developmental toxicology - an integral part of safety evaluation of new drugs

Area of Science:

• Pharmacology and Toxicology
• Developmental Biology
• Public Health

Background:

• The thalidomide tragedy highlighted the critical need for rigorous testing of substances for developmental toxicity.
• Regulatory agencies now mandate pre-clinical evaluation of drugs and food additives for toxicity before market release.
• The increasing number of chemical compounds necessitates efficient and reliable safety testing methods.

Purpose of the Study:

• To review the evolution of testing strategies for developmental toxicity.
• To emphasize the importance of both in vitro and in vivo testing in drug and chemical safety assessment.
• To underscore the role of post-marketing surveillance in ensuring long-term drug safety.

Main Methods:

• Review of historical events and regulatory requirements for drug safety.
• Discussion of in vitro screening methods as preliminary toxicity assessments.
• Emphasis on in vivo studies with pregnant animals for developmental toxicity evaluation.
• Highlighting the significance of post-marketing epidemiological surveys.

Main Results:

• Pre-clinical testing, including in vitro and in vivo studies, is a standard requirement for drug and food additive approval.
• In vitro studies serve as effective pre-screens to prioritize compounds for further in vivo testing.
• Post-marketing epidemiological surveys are essential for definitive drug safety determination.

Conclusions:

• The administration of any drug during pregnancy, particularly the first trimester, carries inherent risks and can be considered an experiment in human teratology.
• Comprehensive pre-clinical testing and post-marketing surveillance are crucial for preventing congenital malformations.
• Continuous development of therapeutic, cosmetic, and food additive chemicals demands ongoing refinement of safety evaluation protocols.